CR11271A - Imidazoles fusionados para el tratamiento del cancer - Google Patents

Imidazoles fusionados para el tratamiento del cancer

Info

Publication number
CR11271A
CR11271A CR11271A CR11271A CR11271A CR 11271 A CR11271 A CR 11271A CR 11271 A CR11271 A CR 11271A CR 11271 A CR11271 A CR 11271A CR 11271 A CR11271 A CR 11271A
Authority
CR
Costa Rica
Prior art keywords
fusionated
imidazoles
cancer
treatment
tautomers
Prior art date
Application number
CR11271A
Other languages
English (en)
Inventor
Swen Holder
Armin Zulch
Thomas Bar
Thomas Maier
Astrid Zimmermann
Thomas Beckers
Volker Gekeler
Hermant Joshi
Yogesh Munot
Umesh Bhise
Sunil Chavan
Sachin Shivatare
Sarvesh Patel
Vikas Gore
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP07118733A external-priority patent/EP2062893A1/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of CR11271A publication Critical patent/CR11271A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Compuesto de formula (I) tautomeros o estereoisomeros de estos, o sus sales donde el anillo B y el imidazol al que esta fusionado.
CR11271A 2007-08-14 2010-02-12 Imidazoles fusionados para el tratamiento del cancer CR11271A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1573MU2007 2007-08-14
EP07118733A EP2062893A1 (en) 2007-10-18 2007-10-18 Fused imidazoles for cancer treatment

Publications (1)

Publication Number Publication Date
CR11271A true CR11271A (es) 2010-05-19

Family

ID=39876840

Family Applications (1)

Application Number Title Priority Date Filing Date
CR11271A CR11271A (es) 2007-08-14 2010-02-12 Imidazoles fusionados para el tratamiento del cancer

Country Status (24)

Country Link
US (2) US8592591B2 (es)
EP (1) EP2176259B1 (es)
JP (1) JP5327652B2 (es)
KR (1) KR20100049589A (es)
CN (1) CN101835776A (es)
AR (1) AR067946A1 (es)
AT (1) ATE503757T1 (es)
AU (1) AU2008288390A1 (es)
CA (1) CA2695251C (es)
CL (1) CL2008002397A1 (es)
CR (1) CR11271A (es)
DE (1) DE602008005894D1 (es)
DO (1) DOP2010000057A (es)
EA (1) EA201000297A1 (es)
EC (1) ECSP109965A (es)
MA (1) MA31609B1 (es)
MX (1) MX2010001745A (es)
PA (1) PA8793301A1 (es)
PE (1) PE20090596A1 (es)
SV (1) SV2010003482A (es)
TN (1) TN2010000071A1 (es)
TW (1) TW200924761A (es)
UY (1) UY31292A1 (es)
WO (1) WO2009021990A1 (es)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410087B2 (en) * 2006-10-19 2013-04-02 Takeda Pharmaceutical Company Limited Indole compound
MX2010001745A (es) * 2007-08-14 2010-03-10 Bayer Schering Pharma Ag Imidazoles fusionados para el tratamiento del cancer.
US20110160232A1 (en) 2007-10-04 2011-06-30 Pingda Ren Certain chemical entities and therapeutic uses thereof
US7868001B2 (en) * 2007-11-02 2011-01-11 Hutchison Medipharma Enterprises Limited Cytokine inhibitors
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
JP5547099B2 (ja) 2008-03-14 2014-07-09 インテリカイン， エルエルシー キナーゼ阻害剤および使用方法
MX2011000216A (es) 2008-07-08 2011-03-29 Intellikine Inc Inhibidores de cinasa y metodos para su uso.
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP5667085B2 (ja) * 2009-02-13 2015-02-12 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ Ａｋｔインヒビターとしての融合されたピリミジン
JP2012521354A (ja) 2009-03-20 2012-09-13 アムジエン・インコーポレーテツド Ｐｉ３キナーゼの阻害薬
JPWO2010125799A1 (ja) 2009-04-27 2012-10-25 塩野義製薬株式会社 Ｐｉ３ｋ阻害活性を有するウレア誘導体
GEP201706639B (en) 2009-08-17 2017-03-27 Intellikine Llc Heterocyclic compounds and uses thereof
JP5641664B2 (ja) 2009-10-30 2014-12-17 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプＪａｎｓｓｅｎ Ｐｈａｒｍａｃｅｕｔｉｃａ Ｎａａｍｌｏｚｅ Ｖｅｎｎｏｏｔｓｃｈａｐ イミダゾ［１，２−ｂ］ピリダジン誘導体およびＰＤＥ１０阻害剤としてのそれらの使用
CA2778265A1 (en) * 2009-11-02 2011-05-05 Abbott Laboratories Imidazopyridines as a novel scaffold for multi-targeted kinase inhibition
EP2526102B1 (en) 2010-01-22 2017-03-08 Fundación Centro Nacional de Investigaciones Oncológicas Carlos III Inhibitors of PI3 kinase
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
AR080754A1 (es) 2010-03-09 2012-05-09 Janssen Pharmaceutica Nv Derivados de imidazo (1,2-a) pirazina y su uso como inhibidores de pde10
US8975265B2 (en) * 2010-07-12 2015-03-10 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-a]pyrimidines and —pyridines
CA2806655A1 (en) 2010-07-28 2012-02-02 Bayer Intellectual Property Gmbh Substituted imidazo[1,2-b]pyridazines
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
DE102011008352A1 (de) * 2011-01-12 2012-07-12 Merck Patent Gmbh 5-([1,2,3]Triazol-4-yl)-7H-pyrrolo-[2,3-d]pyrimidinderivate
JP6130305B2 (ja) 2011-02-23 2017-05-17 インテリカイン， エルエルシー キナーゼ阻害剤の組み合わせおよびそれらの使用
US8772283B2 (en) 2011-04-06 2014-07-08 Taiho Pharmaceutical Co., Ltd. Imidazo-oxazine compound or salt thereof
DK2694510T3 (en) * 2011-04-07 2016-01-18 Bayer Ip Gmbh IMIDAZOPYRIDAZINER AS AKT kinase inhibitors
BR112013033375B1 (pt) 2011-06-27 2022-05-10 Janssen Pharmaceutica N.V Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxa-lina, seu uso, composição farmacêutica que os compreende, processo de preparação dos mesmos, solução estéril e composto intermediário
EP2554544A1 (en) 2011-08-01 2013-02-06 Almirall, S.A. Pyridin-2(1h)-one derivatives as jak inhibitors
EP2802586B1 (en) * 2012-01-10 2016-05-25 Bayer Intellectual Property GmbH Substituted imidazopyrazines as akt kinase inhibitors
US9370517B2 (en) 2012-01-10 2016-06-21 Bayer Intellectual Property Gmbh Substituted pyrazolopyrimidines as Akt kinase inhibitors
AU2013283426B2 (en) 2012-06-26 2018-02-22 Janssen Pharmaceutica Nv Combinations comprising PDE 2 inhibitors such as 1-aryl-4-methyl- [1,2,4] triazolo [4,3-a] quinoxaline compounds and PDE 10 inhibitors for use in the treatment of neurological or metabolic disorders
EP2868660B1 (en) 2012-07-02 2017-12-27 Taiho Pharmaceutical Co., Ltd. Antitumor effect potentiator comprising an imidazooxazine compound
WO2014009305A1 (en) 2012-07-09 2014-01-16 Janssen Pharmaceutica Nv Inhibitors of phosphodiesterase 10 enzyme
WO2014153509A1 (en) 2013-03-22 2014-09-25 Millennium Pharmaceuticals, Inc. Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
GB201321732D0 (en) * 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
JPWO2016136928A1 (ja) 2015-02-27 2017-08-31 大鵬薬品工業株式会社 イミダゾオキサジンの結晶、当該結晶を含む医薬組成物、及び当該結晶の製造方法
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
MA46589A (fr) * 2016-10-24 2019-08-28 Yumanity Therapeutics Inc Composés et utilisations de ces derniers
EP3566055B1 (en) 2017-01-06 2025-03-12 Janssen Pharmaceutica NV Scd inhibitor for the treatment of neurological disorders
CA3083000A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. Compounds and uses thereof
ES3043183T3 (en) 2018-03-23 2025-11-25 Janssen Pharmaceutica Nv Compounds and uses thereof
US12324807B2 (en) 2018-06-01 2025-06-10 Cornell University Combination therapy for PI3K-associated disease or disorder
MX2021008903A (es) 2019-01-24 2021-11-04 Yumanity Therapeutics Inc Compuestos y usos de los mismos.
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CN118812530B (zh) * 2023-04-18 2026-02-13 中国科学院大连化学物理研究所 一种Pd/C双组分体系催化木质素及模型化合物制备咪唑吡啶类化合物的方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE361297T1 (de) 2000-03-31 2007-05-15 Ortho Mcneil Pharm Inc Phenyl-substituierte imidazopyridine
JP3729343B2 (ja) * 2000-04-27 2005-12-21 アステラス製薬株式会社 縮合ヘテロアリール誘導体
AU2004233828B2 (en) * 2003-04-24 2009-05-28 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CA2534292A1 (en) 2003-07-30 2005-02-17 Laboratorios S.A.L.V.A.T., S.A. Substituted imidazopyrimidines for the prevention and treatment of cancer
DE602005026509D1 (de) * 2004-04-09 2011-04-07 Merck Sharp & Dohme Hemmer der akt aktivität
EP1784175A4 (en) * 2004-08-23 2009-07-22 Merck & Co Inc INHIBITORS OF ACT ACTIVITY
AU2005316826A1 (en) * 2004-12-15 2006-06-22 Merck Sharp & Dohme Corp. Inhibitors of Akt activity
CN101263142A (zh) * 2005-05-20 2008-09-10 阿雷生物药品公司 Raf抑制剂化合物及其使用方法
WO2007025090A2 (en) * 2005-08-25 2007-03-01 Kalypsys, Inc. Heterobicyclic and - tricyclic inhibitors of mapk/erk kinase
US7709468B2 (en) * 2005-09-02 2010-05-04 Abbott Laboratories Imidazo based heterocycles
PE20070978A1 (es) * 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
US7530313B2 (en) 2006-05-12 2009-05-12 Day & Zimmerman, Inc. Self-destruct fuze delay mechanism
MX2010001745A (es) * 2007-08-14 2010-03-10 Bayer Schering Pharma Ag Imidazoles fusionados para el tratamiento del cancer.

Also Published As

Publication number Publication date
PE20090596A1 (es) 2009-06-07
CA2695251A1 (en) 2009-02-19
TN2010000071A1 (en) 2011-09-26
WO2009021990A1 (en) 2009-02-19
JP2010535847A (ja) 2010-11-25
CA2695251C (en) 2016-06-21
DE602008005894D1 (de) 2011-05-12
JP5327652B2 (ja) 2013-10-30
MA31609B1 (fr) 2010-08-02
TW200924761A (en) 2009-06-16
KR20100049589A (ko) 2010-05-12
US9387204B2 (en) 2016-07-12
ATE503757T1 (de) 2011-04-15
MX2010001745A (es) 2010-03-10
DOP2010000057A (es) 2010-04-15
SV2010003482A (es) 2010-07-06
ECSP109965A (es) 2010-03-31
CN101835776A (zh) 2010-09-15
EP2176259B1 (en) 2011-03-30
US20090156604A1 (en) 2009-06-18
US8592591B2 (en) 2013-11-26
EA201000297A1 (ru) 2010-08-30
EP2176259A1 (en) 2010-04-21
US20140088110A1 (en) 2014-03-27
AU2008288390A1 (en) 2009-02-19
UY31292A1 (es) 2009-03-31
CL2008002397A1 (es) 2009-09-25
AR067946A1 (es) 2009-10-28
PA8793301A1 (es) 2009-04-23

Similar Documents

Publication Publication Date Title
CR11271A (es) Imidazoles fusionados para el tratamiento del cancer
CL2014000887A1 (es) Compuestos derivados de 1-fenil-imidazol condensado y sus sales, inhibidores de proteinas quinasas; composicion farmaceutica que los comprende; y su uso para el tratamiento de una condicion donde se desea la inhibicion de la quinasa del fgfr tal como cancer.
GT200600394A (es) Benzimidazoles sustituidos y metodos para usarlos como inhibidores de las quinasas asociadas con la tumorigenesis.
CU20200099A7 (es) Compuestos derivados sustituidos de ácidos 6-carboxílicos de bencimidazoles y 4-aza-, 5-aza y 7-aza- benzimidazoles como agonistas glpr-1 útiles para el tratamiento o prevención de enfermedades cardiometabólicas y asociadas
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
MX373786B (es) Derivados de pirimidin-2,4-diamina para el tratamiento de cáncer.
CL2008001705A1 (es) Compuestos derivados de heterociclos de nitrogeno; y uso del compuesto para el tratamiento de enfermedades o trastornos relacionados con el receptor de histamina h3.
ECSP088536A (es) DERIVADOS DE PIRIDO-, PIRAZO- Y PIRIMIDO-PIRIMIDINA COMO INHIBIDORES DE mTOR
EA201691625A1 (ru) Ароматические гетероциклические соединения как противовоспалительные соединения
HN2010000313A (es) Pirimidinas biciclicas fusionadas
NI201200023A (es) Derivados de 5-fluoropirimidinona
MX2012012527A (es) Compuestos quimicos.
CR11757A (es) Compuestos de triazina como inhibidores mtor y quinasa pi3
UY34261A (es) Compuestos fungicidas de 1-{2-[2-halo-4-(4-halogen-fenoxi)-fenil]-2-alcoxi-2-ciclil-etil}-1h-[1,2,4]triazol sustituidos
SV2011003809A (es) Derivados de heteroarilo como inhibidores de dgat1
DOP2011000260A (es) Pirimidinas fusionadas
NI200900151A (es) Nuevo procedimiento de síntesis de la agomelatina.
TN2015000521A1 (en) Processes of making and crystalline forms of a mdm2 inhibitor
EA200971068A1 (ru) Триазолиламинопиримидиновые соединения
CR11412A (es) Inhibidores de cinesina como productos terapeuticos para el cancer
CU24263B1 (es) Derivados de imidazopiridazinas inhibidores de quinasa akt, útiles para el tratamiento del cáncer
NI200900153A (es) Nuevo procedimiento de síntesis de la agomelatina.
AR108461A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer
CR20130306A (es) Compuestos y su uso
EA201390499A1 (ru) Соединения, подходящие для ингибирования снк1

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)